Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole plus everolimus for previously treated metastatic non-small cell lung cancer
ACTRN12607000218493Phase 2Recruiting
- Sponsor
- Royal Adelaide Hospital
- Start
- May 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of letrozole and everolimus in non-small cell lung cancer (NSCLC), sponsored by Royal Adelaide Hospital. Primary endpoint: Response rate. Started May 2007; status: recruiting.
02
Drugs
letrozoleeverolimus
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ACTRN12607000218493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000218493.